JP6877003B2 - イメージング質量分析の前処理方法 - Google Patents
イメージング質量分析の前処理方法 Download PDFInfo
- Publication number
- JP6877003B2 JP6877003B2 JP2016231372A JP2016231372A JP6877003B2 JP 6877003 B2 JP6877003 B2 JP 6877003B2 JP 2016231372 A JP2016231372 A JP 2016231372A JP 2016231372 A JP2016231372 A JP 2016231372A JP 6877003 B2 JP6877003 B2 JP 6877003B2
- Authority
- JP
- Japan
- Prior art keywords
- sample
- acid
- mass spectrometry
- imaging mass
- pretreatment method
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 238000001871 ion mobility spectroscopy Methods 0.000 title claims description 15
- 238000002203 pretreatment Methods 0.000 title claims description 8
- 239000002253 acid Substances 0.000 claims description 25
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 claims description 14
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 claims description 7
- 235000019253 formic acid Nutrition 0.000 claims description 7
- 238000000034 method Methods 0.000 claims description 5
- 102000004169 proteins and genes Human genes 0.000 claims description 5
- 108090000623 proteins and genes Proteins 0.000 claims description 5
- 108010090849 Amyloid beta-Peptides Proteins 0.000 claims description 2
- 102000013455 Amyloid beta-Peptides Human genes 0.000 claims description 2
- 239000000523 sample Substances 0.000 description 37
- 239000011521 glass Substances 0.000 description 14
- 150000002500 ions Chemical class 0.000 description 12
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 11
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 9
- 238000004458 analytical method Methods 0.000 description 9
- 238000000816 matrix-assisted laser desorption--ionisation Methods 0.000 description 8
- 238000000926 separation method Methods 0.000 description 8
- 238000003384 imaging method Methods 0.000 description 7
- 239000011159 matrix material Substances 0.000 description 6
- WXTMDXOMEHJXQO-UHFFFAOYSA-N 2,5-dihydroxybenzoic acid Chemical compound OC(=O)C1=CC(O)=CC=C1O WXTMDXOMEHJXQO-UHFFFAOYSA-N 0.000 description 4
- BRARRAHGNDUELT-UHFFFAOYSA-N 3-hydroxypicolinic acid Chemical compound OC(=O)C1=NC=CC=C1O BRARRAHGNDUELT-UHFFFAOYSA-N 0.000 description 4
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- PCMORTLOPMLEFB-UHFFFAOYSA-N sinapic acid Chemical compound COC1=CC(C=CC(O)=O)=CC(OC)=C1O PCMORTLOPMLEFB-UHFFFAOYSA-N 0.000 description 4
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 239000012472 biological sample Substances 0.000 description 3
- 238000001574 biopsy Methods 0.000 description 3
- 210000004556 brain Anatomy 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 150000002632 lipids Chemical class 0.000 description 3
- 208000024827 Alzheimer disease Diseases 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 101710150875 TAR DNA-binding protein 43 Proteins 0.000 description 2
- 102100040347 TAR DNA-binding protein 43 Human genes 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 230000036571 hydration Effects 0.000 description 2
- 238000006703 hydration reaction Methods 0.000 description 2
- 238000000752 ionisation method Methods 0.000 description 2
- -1 lipids Chemical class 0.000 description 2
- 238000004949 mass spectrometry Methods 0.000 description 2
- 238000001819 mass spectrum Methods 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- PCMORTLOPMLEFB-ONEGZZNKSA-N sinapic acid Chemical compound COC1=CC(\C=C\C(O)=O)=CC(OC)=C1O PCMORTLOPMLEFB-ONEGZZNKSA-N 0.000 description 2
- 239000007921 spray Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 238000001269 time-of-flight mass spectrometry Methods 0.000 description 2
- KSEBMYQBYZTDHS-HWKANZROSA-M (E)-Ferulic acid Natural products COC1=CC(\C=C\C([O-])=O)=CC=C1O KSEBMYQBYZTDHS-HWKANZROSA-M 0.000 description 1
- NZNMSOFKMUBTKW-UHFFFAOYSA-N Cyclohexanecarboxylic acid Natural products OC(=O)C1CCCCC1 NZNMSOFKMUBTKW-UHFFFAOYSA-N 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 208000025966 Neurological disease Diseases 0.000 description 1
- 102000003802 alpha-Synuclein Human genes 0.000 description 1
- 108090000185 alpha-Synuclein Proteins 0.000 description 1
- AFVLVVWMAFSXCK-VMPITWQZSA-N alpha-cyano-4-hydroxycinnamic acid Chemical compound OC(=O)C(\C#N)=C\C1=CC=C(O)C=C1 AFVLVVWMAFSXCK-VMPITWQZSA-N 0.000 description 1
- 108010064539 amyloid beta-protein (1-42) Proteins 0.000 description 1
- DZHSAHHDTRWUTF-SIQRNXPUSA-N amyloid-beta polypeptide 42 Chemical compound C([C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)NCC(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(O)=O)[C@@H](C)CC)C(C)C)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C(C)C)C1=CC=CC=C1 DZHSAHHDTRWUTF-SIQRNXPUSA-N 0.000 description 1
- NUZWLKWWNNJHPT-UHFFFAOYSA-N anthralin Chemical compound C1C2=CC=CC(O)=C2C(=O)C2=C1C=CC=C2O NUZWLKWWNNJHPT-UHFFFAOYSA-N 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 229920001222 biopolymer Polymers 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 230000005684 electric field Effects 0.000 description 1
- IDGUHHHQCWSQLU-UHFFFAOYSA-N ethanol;hydrate Chemical compound O.CCO IDGUHHHQCWSQLU-UHFFFAOYSA-N 0.000 description 1
- 235000001785 ferulic acid Nutrition 0.000 description 1
- KSEBMYQBYZTDHS-HWKANZROSA-N ferulic acid Chemical compound COC1=CC(\C=C\C(O)=O)=CC=C1O KSEBMYQBYZTDHS-HWKANZROSA-N 0.000 description 1
- 229940114124 ferulic acid Drugs 0.000 description 1
- KSEBMYQBYZTDHS-UHFFFAOYSA-N ferulic acid Natural products COC1=CC(C=CC(O)=O)=CC=C1O KSEBMYQBYZTDHS-UHFFFAOYSA-N 0.000 description 1
- 229960005219 gentisic acid Drugs 0.000 description 1
- 229930005346 hydroxycinnamic acid Natural products 0.000 description 1
- 235000010359 hydroxycinnamic acids Nutrition 0.000 description 1
- 150000002605 large molecules Chemical class 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 229920001059 synthetic polymer Polymers 0.000 description 1
- 102000013498 tau Proteins Human genes 0.000 description 1
- 108010026424 tau Proteins Proteins 0.000 description 1
- 239000010409 thin film Substances 0.000 description 1
- NGSWKAQJJWESNS-ZZXKWVIFSA-N trans-4-coumaric acid Chemical compound OC(=O)\C=C\C1=CC=C(O)C=C1 NGSWKAQJJWESNS-ZZXKWVIFSA-N 0.000 description 1
- QURCVMIEKCOAJU-UHFFFAOYSA-N trans-isoferulic acid Natural products COC1=CC=C(C=CC(O)=O)C=C1O QURCVMIEKCOAJU-UHFFFAOYSA-N 0.000 description 1
- 239000012808 vapor phase Substances 0.000 description 1
Images
Landscapes
- Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
Description
試料は、イオン化しにくい性質を有する難イオン化性の試料であり、例えば生体組織切片である。生体組織切片は、タンパク質凝集体を含有する組織切片である。凝集体を形成するタンパク質は、例えばアミロイドβ、タウ、αシヌクレイン、ハンチントン、TDP-43(TAR DNA-binding protein 43 kDa)である。
次に酸蒸気処理された試料に、例えばエアブラシにより均一な薄膜状のマトリックスが塗布され、乾燥により結晶化される。マトリックスはレーザーエネルギー伝達の仲介を可能とするものであれば特に限定されるものではないが、例えばシナピン酸(3,5-ジメトキシ-4-ヒドロキシケイ皮酸)、CHCA(α-シアノ-4-ヒドロキシケイ皮酸)、フェルラ酸(trans-4-ヒドロキシ-3-メトキシケイ皮酸)、ゲンチジン酸(2,5-ジヒドロキシ安息香酸)、HPA(3-ヒドロキシピコリン酸)、ジスラノール(1,8-ジヒドロキシ-9,10-ジヒドロアントラセン-9-オン)等を使用することができ、好ましくはシナピン酸である。
イオン源200は試料の物性により適宜選択可能であるが、例えばMALDIである。MALDIは、タンパク質等の生体高分子解析に好適なイオン化方法である。MALDIのイオン化法は、おもにマトリックス由来のH+(プロトン)が試料に付加した擬分子イオンを生成するため、非常にソフトなイオン化であり、また多価イオンを生成しにくいので解釈の容易なスペクトルを得ることが可能である。また難溶解性の試料でも固相のままマトリックスと混合することによってイオン化させることが可能である。イオン化源のレーザは、例えば窒素レーザやYAGレーザ等である。
飛行時間型質量分析計TOF-MSでは、レーザによりイオン化された物質は、一定の電場によりエネルギーを受け、飛行を始める。ドリフト領域では、質量の小さいものはスピードが速く、大きいものはスピードが遅いことから、検出器への到達時間に差が生じ、その時間差を計測しそれを質量に変換することにより質量スペクトルが得られる。
イメージング専用のソフトウエアにより、取得した質量スペクトルを下にデータ解析が行われ、画像として可視化される。
200:イオン源
300:分離分析部
400:データ処理部
900:イメージング質量分析装置
Claims (4)
- 試料台に載置されたアミロイドβを含有する組織切片である試料を密閉容器内に設置する工程と、
熱により揮散したガス状のギ酸を該密閉容器内に充満させ、試料をガス状のギ酸に曝す酸蒸気処理を行う工程と、
を有することを特徴とするイメージング質量分析の前処理方法。 - 前記試料は、難イオン化性であることを特徴とする請求項1に記載のイメージング質量分析の前処理方法。
- 前記試料は、タンパク質凝集体を含有する組織切片であることを特徴とする請求項1又は2に記載のイメージング質量分析の前処理方法。
- 前記酸蒸気処理は60℃〜80℃にて行うことを特徴とする請求項1乃至3の何れか1項に記載のイメージング質量分析の前処理方法。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2016231372A JP6877003B2 (ja) | 2016-11-29 | 2016-11-29 | イメージング質量分析の前処理方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2016231372A JP6877003B2 (ja) | 2016-11-29 | 2016-11-29 | イメージング質量分析の前処理方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2018087760A JP2018087760A (ja) | 2018-06-07 |
JP6877003B2 true JP6877003B2 (ja) | 2021-05-26 |
Family
ID=62494356
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2016231372A Active JP6877003B2 (ja) | 2016-11-29 | 2016-11-29 | イメージング質量分析の前処理方法 |
Country Status (1)
Country | Link |
---|---|
JP (1) | JP6877003B2 (ja) |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2053406A3 (en) * | 2001-07-16 | 2009-06-24 | caprotec bioanalytics GmbH | Capture compounds, collections thereof and methods for analyzing the proteome and complex compositions |
JP4636859B2 (ja) * | 2004-11-25 | 2011-02-23 | キヤノン株式会社 | 情報取得方法 |
US20070134802A1 (en) * | 2005-06-30 | 2007-06-14 | Heinz Doebeli | Ionization modifier for mass spectrometry |
JP2012032298A (ja) * | 2010-07-30 | 2012-02-16 | Nippi:Kk | 糖タンパク質の試料調製方法および分析方法 |
JP5518152B2 (ja) * | 2012-09-05 | 2014-06-11 | キヤノン株式会社 | 質量分析装置、質量分析用組成物及び質量分析方法 |
WO2014162557A1 (ja) * | 2013-04-04 | 2014-10-09 | 株式会社島津製作所 | Maldi用試料調製方法及び試料調製装置 |
-
2016
- 2016-11-29 JP JP2016231372A patent/JP6877003B2/ja active Active
Also Published As
Publication number | Publication date |
---|---|
JP2018087760A (ja) | 2018-06-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Baker et al. | Recent advancements in matrix-assisted laser desorption/ionization mass spectrometry imaging | |
Meriaux et al. | Liquid ionic matrixes for MALDI mass spectrometry imaging of lipids | |
Bonnel et al. | Multivariate analyses for biomarkers hunting and validation through on-tissue bottom-up or in-source decay in MALDI-MSI: application to prostate cancer | |
Yoon et al. | Biological tissue sample preparation for time-of-flight secondary ion mass spectrometry (ToF–SIMS) imaging | |
Belov et al. | Design and performance of a novel interface for combined matrix-assisted laser desorption ionization at elevated pressure and electrospray ionization with orbitrap mass spectrometry | |
Taban et al. | Imaging of peptides in the rat brain using MALDI-FTICR mass spectrometry | |
Pól et al. | Molecular mass spectrometry imaging in biomedical and life science research | |
Touboul et al. | Mass spectrometry imaging: Towards a lipid microscope? | |
Schaepe et al. | Imaging of lipids in native human bone sections using TOF–secondary ion mass spectrometry, atmospheric pressure scanning microprobe matrix-assisted laser desorption/ionization Orbitrap mass spectrometry, and Orbitrap–secondary ion mass spectrometry | |
Chen et al. | A high resolution atmospheric pressure matrix-assisted laser desorption/ionization-quadrupole-orbitrap MS platform enables in situ analysis of biomolecules by multi-mode ionization and acquisition | |
Trimpin et al. | New ionization processes and applications for use in mass spectrometry | |
JP2012529058A (ja) | レーザースプレーイオン化を用いる質量分析 | |
Liu et al. | Mass spectrometry imaging of small molecules using desorption/ionization on silicon | |
Mano et al. | Biomedical and biological mass spectrometry | |
Schröter et al. | The combination of 2, 5-dihydroxybenzoic acid and 2, 5-dihydroxyacetophenone matrices for unequivocal assignment of phosphatidylethanolamine species in complex mixtures | |
Harron et al. | High mass resolution tissue imaging at atmospheric pressure using laserspray ionization mass spectrometry | |
Rao et al. | Pharmacokinetic study based on a matrix-assisted laser desorption/ionization quadrupole ion trap time-of-flight imaging mass microscope combined with a novel relative exposure approach: a case of octreotide in mouse target tissues | |
Dowlatshahi Pour et al. | An investigation on the mechanism of sublimed DHB matrix on molecular ion yields in SIMS imaging of brain tissue | |
Nakanishi et al. | Topologies of amyloidogenic proteins in Congo red-positive sliced sections of formalin-fixed paraffin embedded tissues by MALDI-MS imaging coupled with on-tissue tryptic digestion | |
Susniak et al. | Recent developments in MALDI MSI application in plant tissues analysis | |
El-Baba et al. | Toward high spatial resolution sampling and characterization of biological tissue surfaces using mass spectrometry | |
JP6877003B2 (ja) | イメージング質量分析の前処理方法 | |
Quanico et al. | Combined MALDI mass spectrometry imaging and parafilm-assisted microdissection-based LC-MS/MS workflows in the study of the brain | |
Touboul et al. | MALDI mass spectrometry imaging of lipids and primary metabolites on rat brain sections | |
Thomas et al. | LDI MS imaging at high specificity and sensitivity |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
RD01 | Notification of change of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7426 Effective date: 20170106 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20170106 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20191118 |
|
A711 | Notification of change in applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A712 Effective date: 20191118 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20191118 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20200821 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20200929 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20201028 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20210330 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20210419 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 6877003 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE Ref document number: 6877003 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |